Daily Endocrinology Research Analysis
Analyzed 167 papers and selected 3 impactful papers.
Summary
Three papers stand out today: a mechanistic translational study uncovers a microbiota–melibiose–GLO1 axis mediating canagliflozin’s renoprotection in diabetic kidney disease; a JCEM genetic study links biallelic Notch pathway variants to congenital hypothyroidism with zebrafish validation; and an RCT shows closed‑loop automated insulin delivery improves intrapartum and early postpartum glycemia in type 1 diabetes. Together they advance mechanisms, genomics, and peripartum care in endocrinology.
Research Themes
- Gut–kidney axis and microbiome-mediated mechanisms in diabetes complications
- Genomic architecture and functional validation in congenital hypothyroidism
- Peripartum automated insulin delivery improving glycemic control
Selected Articles
1. Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota-Dependent Manner.
In humans and mice, canagliflozin’s renoprotection was linked to remodeling of the gut microbiome, enrichment of Roseburia intestinalis, and increased melibiose, which activates GLO1 and suppresses AGE–RAGE signaling to preserve glomerular endothelial integrity. FMT, Roseburia, and melibiose administration recapitulated benefits, and a melibiose precursor reduced albuminuria in early DKD patients.
Impact: This study delineates a causal gut–kidney axis mediator (melibiose) and a druggable enzyme (GLO1) underlying SGLT2 inhibitor renoprotection, bridging multi-omics, gnotobiotics, and human supplementation.
Clinical Implications: Suggests microbiome/metabolite-targeted adjuncts (e.g., melibiose precursors, Roseburia-promoting strategies) could augment DKD management alongside SGLT2 inhibitors; requires controlled clinical trials before adoption.
Key Findings
- In a 26-week human cohort (n=170), canagliflozin enriched Roseburia intestinalis and increased plasma melibiose.
- Melibiose directly bound/activated GLO1, reduced methylglyoxal, and suppressed AGE–RAGE signaling, preserving glomerular endothelium.
- FMT from canagliflozin-treated donors, Roseburia administration, or melibiose reproduced renoprotection in mice.
- Oral melibiose precursor reduced albuminuria in patients with early-stage DKD.
Methodological Strengths
- Translational design integrating human cohort, gnotobiotic FMT, targeted metabolomics, and mechanistic assays.
- Convergent validation across multiple systems (microbiome, purified metabolite, enzyme binding/activation, animal models).
Limitations
- Human components were non-randomized with modest sample sizes and short duration.
- Clinical supplementation used a precursor and lacked blinded, controlled outcome assessment.
Future Directions: Randomized, placebo-controlled trials of melibiose (or Roseburia-targeted strategies) in DKD; exploration of GLO1 agonism and patient stratification by microbiome/metabolome signatures.
Canagliflozin reduces albuminuria in patients with diabetic kidney disease (DKD) beyond its glucose-lowering effect, but the mechanisms remain unclear. We analyzed 85 patients treated with canagliflozin and 85 controls over 26 weeks to explore whether the gut microbiome and its metabolites contribute to renoprotection. Canagliflozin remodeled the gut microbiota, notably enriching Roseburia intestinalis and increasing plasma melibiose levels. In mice, canagliflozin alleviated glomerular endothelial injury and albuminuria. Similar effects were replicated by fecal microbiota transplantation, Roseburia intestinalis, or melibiose administration. Mechanistically, melibiose bound to and activated glyoxalase 1, reduced methylglyoxal, and suppressed the AGE-RAGE pathway, preserving glomerular endothelial integrity. Furthermore, oral melibiose precursor supplementation reduced albuminuria in patients with early-stage DKD. These findings suggest the involvement of a gut-kidney axis in the renoprotective effects of canagliflozin and indicate that melibiose may serve as a potential therapeutic strategy for DKD.
2. First large-scale screening of Notch biallelic variants implicates novel candidate genes in congenital hypothyroidism.
Among 417 genetically unsolved CH cases, 21 harbored biallelic variants across 11 Notch pathway genes with zebrafish validation of thyroid dysfunction. Notch-variant patients had higher initial FT4 yet required higher levothyroxine doses than DUOX2 cases, expanding CH’s genetic landscape and suggesting pathway-specific management.
Impact: Provides first large-scale human evidence implicating Notch signaling in CH with in vivo functional validation, informing diagnostic panels and pathophysiology.
Clinical Implications: Supports adding Notch pathway genes to CH genetic testing, and alerts clinicians that Notch-variant patients may require higher levothyroxine doses despite milder biochemistry at diagnosis.
Key Findings
- Biallelic variants in 11 Notch pathway genes were found in 21/417 genetically unsolved CH patients (~5%).
- Zebrafish knockdown showed reduced thyroglobulin, abnormal thyroid morphology, elevated tsh, and decreased T4, supporting pathogenicity.
- Notch-variant patients had higher initial FT4 but needed higher levothyroxine doses than DUOX2 patients.
Methodological Strengths
- Large cohort with systematic WES and targeted pathway interrogation.
- Orthogonal functional validation in vivo (zebrafish morpholino knockdown) linking genotype to thyroid phenotype.
Limitations
- Biallelic variants were rare and require replication in diverse populations.
- Functional assays were performed in zebrafish; human tissue validation and mechanistic detail remain to be defined.
Future Directions: Expand screening to multi-ethnic cohorts, perform CRISPR models for precise mechanistic mapping, and evaluate genotype-informed levothyroxine dosing strategies.
CONTEXT: Congenital hypothyroidism (CH) is a major preventable cause of developmental and cognitive impairment. Current genetic testing identifies causative variants for only half of cases, leaving the majority without a molecular diagnosis. Although animal studies implicate Notch signaling in thyroid development, its role in human CH remains unexplored. OBJECTIVE: To investigate whether Notch pathway variants contribute to genetically unexplained CH. DESIGN: Genetic screening using whole-exome sequencing with zebrafish functional validation. SETTING: Endocrinology outpatient clinic at Shanghai Ninth People's Hospital. PATIENTS OR OTHER PARTICIPANTS: 781 unrelated Chinese patients with CH. After identifying variants in 21 known causative genes in 364 patients, the remaining 417 unsolved cases were screened for variants in 77 Notch signaling pathway genes. MAIN OUTCOME MEASURE(S): Identification of biallelic Notch pathway variants; functional validation through zebrafish morpholino knockdown experiments assessing thyroid morphology and hormone production; clinical phenotype including thyroid function parameters, thyroid morphology, and levothyroxine dosage requirements; comparison with 267 DUOX2 patients. RESULTS: We identified biallelic variants in 11 Notch pathway genes (NEURL1, CNTN6, NOTCH3, DTX1, DVL1, DTX2, ATXN1, SPEN, CTBP2, NCOR2, MAMLD1) in 21 patients. Zebrafish knockdown provided functional support for the potential pathogenic role of these genes, showing reduced thyroglobulin expression, abnormal morphology, elevated tsh levels, and decreased T4. Notch-variant patients showed higher initial FT4 but required significantly higher levothyroxine doses than DUOX2 patients. CONCLUSIONS: Notch pathway variants may contribute to approximately 5% of genetically unexplained CH. Variants across multiple pathway components collectively impair thyroid function. These findings suggest a potential expansion of CH genetic architecture and suggest that Notch-variant patients may require enhanced hormone replacement despite milder initial presentation, warranting pathway-specific screening.
3. Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial.
In this prespecified RCT analysis (n=44), closed-loop AID increased intrapartum time-in-range by 13.2 percentage points versus standard care and reduced postpartum hypoglycemia, while dramatically lowering need for IV insulin. No severe hypoglycemia or DKA occurred with AID.
Impact: Provides high-quality randomized evidence supporting peripartum AID use with clear efficacy and safety signals in a critical period for mother–infant outcomes.
Clinical Implications: Closed-loop AID can be continued through labor and early postpartum to improve glycemic control and reduce IV insulin needs in type 1 diabetes; protocols should integrate AID into intrapartum pathways with monitoring.
Key Findings
- Intrapartum time-in-range (63–140 mg/dL) was higher with AID: 79.6% vs 64.8% (adjusted difference 13.2 pp; 95% CI 5.2–21.2).
- Postpartum week 1 hypoglycemia time <70 mg/dL was lower with AID: 1.7% vs 3.2% (difference −1.8 pp).
- IV insulin use intrapartum was 2% with AID vs 45% with standard care; no severe hypoglycemia or DKA in AID.
Methodological Strengths
- Randomized design with prespecified intrapartum/postpartum analyses and CGM-based endpoints.
- Adjusted analyses for baseline factors and multicenter conduct.
Limitations
- Modest sample size limits precision and subgroup analyses.
- Open-label nature and potential selection bias (89% continued AID intrapartum).
Future Directions: Larger, pragmatic RCTs across diverse labor settings and integration with neonatal outcomes; protocolization of AID adjustments during induction, cesarean, and postpartum lactation.
OBJECTIVE: Following the demonstrated improvement in pregnancy glycemia with Control-IQ closed loop in the Closed loop Insulin delivery by glucose Responsive Computer algorithms In Type 1 diabetes pregnancies (CIRCUIT) trial, we compared intrapartum and early postpartum glycemic effectiveness and safety with standard care in type 1 diabetes. RESEARCH DESIGN AND METHODS: The primary outcome of this prespecified analysis was percentage of time in pregnancy-specific glucose range (63-140 mg/dL) during the 24 h prior to childbirth, measured by continuous glucose monitoring. A key secondary outcome was percentage of time at <70 mg/dL in the first postpartum week, with additional secondary outcomes including continuous glucose monitoring metrics through 6 weeks postpartum. Analyses were adjusted for baseline measure, insulin delivery mode, and site. RESULTS: In the intrapartum period (24 h before delivery), 39 of 44 (89%) participants continued closed loop. Intravenous insulin was used intrapartum by one (2%) closed loop participant and 20 (45%) standard care participants (P < 0.001). Intrapartum closed loop users spent more time in pregnancy-specific glucose range (79.6% vs. 64.8%) than the standard-care group (mean adjusted difference 13.2 percentage points; 95% CI 5.2, 21.2). In the first postpartum week, the closed loop group spent less time <70 mg/dL (1.7% vs. 3.2%; mean adjusted difference -1.8 percentage points; 95% CI -0.9 to -2.7) compared with the standard care group. No maternal severe hypoglycemia occurred in the closed loop group, while one episode occurred in the standard care group postpartum. No diabetic ketoacidosis occurred in either group. CONCLUSIONS: Use of this closed loop system resulted in superior intrapartum and early postpartum glycemia compared with standard care, without safety concerns. Together with previous results, this supports use of this closed loop system throughout pregnancy, labor, and the early postpartum period.